

Dora Dias-Santagata

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2957212/publications.pdf>

Version: 2024-02-01

58
papers

5,123
citations

257450

24
h-index

189892

50
g-index

59
all docs

59
docs citations

59
times ranked

8746
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | t(4;12)(q12;p13) ETV6-rearranged AML without eosinophilia does not involve PDGFRA: relevance for imatinib insensitivity. <i>Blood Advances</i> , 2022, 6, 818-827. | 5.2 | 5 |
| 2 | American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment. <i>Head and Neck</i> , 2022, 44, 1277-1300. | 2.0 | 41 |
| 3 | Diagnostic Value of MAML2 Rearrangements in Mucoepidermoid Carcinoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4322. | 4.1 | 7 |
| 4 | Abstract 5248: CDK4/6 inhibition (CDK4/6i) is effective in the real-world setting for hormone receptor-positive metastatic breast cancer (HR+ MBC) with <i>ESR1</i> mutations and fusions. <i>Cancer Research</i> , 2022, 82, 5248-5248. | 0.9 | 0 |
| 5 | Merkel Cell Carcinoma of Unknown Primary: Immunohistochemical and Molecular Analyses Reveal Distinct UV-Signature/MCPyV-Negative and High Immunogenicity/MCPyV-Positive Profiles. <i>Cancers</i> , 2021, 13, 1621. | 3.7 | 10 |
| 6 | Cribiform-Morular Thyroid Carcinoma Is a Distinct Thyroid Malignancy of Uncertain Cytogenesis. <i>Endocrine Pathology</i> , 2021, 32, 327-335. | 9.0 | 25 |
| 7 | Mucoacinar Carcinoma. <i>American Journal of Surgical Pathology</i> , 2021, 45, 1028-1037. | 3.7 | 20 |
| 8 | Prognostic Roles of BRAF, KIT, NRAS, IGF2R and SF3B1 Mutations in Mucosal Melanomas. <i>Cells</i> , 2021, 10, 2216. | 4.1 | 8 |
| 9 | Intraductal carcinoma of the salivary gland with NCOA4-RET: expanding the morphologic spectrum and an algorithmic diagnostic approach. <i>Human Pathology</i> , 2021, 114, 74-89. | 2.0 | 5 |
| 10 | BRAF ^{V600E} Mutation is Associated with an Increased Risk of Papillary Thyroid Cancer Recurrence. <i>World Journal of Surgery</i> , 2020, 44, 2685-2691. | 1.6 | 26 |
| 11 | Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers. <i>Clinical Cancer Research</i> , 2020, 26, 1877-1885. | 7.0 | 67 |
| 12 | Response to RET-Specific Therapy in <i>RET</i> Fusion-Positive Anaplastic Thyroid Carcinoma. <i>Thyroid</i> , 2020, 30, 1384-1389. | 4.5 | 25 |
| 13 | Novel gene fusions in secretory carcinoma of the salivary glands: enlarging the ETV6 family. <i>Human Pathology</i> , 2019, 83, 50-58. | 2.0 | 70 |
| 14 | Novel and established EWSR1 gene fusions and associations identified by next-generation sequencing and fluorescence in-situ hybridization. <i>Human Pathology</i> , 2019, 93, 65-73. | 2.0 | 27 |
| 15 | Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. <i>Nature Medicine</i> , 2019, 25, 1415-1421. | 30.7 | 359 |
| 16 | PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 4375-4387. | 7.0 | 26 |
| 17 | Clinically Integrated Molecular Diagnostics in Adenoid Cystic Carcinoma. <i>Oncologist</i> , 2019, 24, 1356-1367. | 3.7 | 18 |
| 18 | <i>EGFR</i> -Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes. <i>Journal of Clinical Oncology</i> , 2019, 37, 278-285. | 1.6 | 286 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Clinicopathological and molecular features of SF3B1-mutated myeloproliferative neoplasms. <i>Human Pathology</i> , 2019, 86, 1-11. | 2.0 | 24 |
| 20 | Complete Remission Following Pembrolizumab in a Woman with Mismatch Repair-Deficient Endometrial Cancer and a Germline <i>BRCA1</i> Mutation. <i>Oncologist</i> , 2018, 23, 650-653. | 3.7 | 8 |
| 21 | Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in <i>BRAF</i> ^{V600E} Colorectal Cancer. <i>Cancer Discovery</i> , 2018, 8, 417-427. | 9.4 | 61 |
| 22 | Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer. <i>JCO Precision Oncology</i> , 2018, 2018, 1-15. | 3.0 | 17 |
| 23 | Artificial Intelligence Approach for Variant Reporting. <i>JCO Clinical Cancer Informatics</i> , 2018, 2, 1-13. | 2.1 | 13 |
| 24 | Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer. <i>JCO Precision Oncology</i> , 2018, 2018, 1-13. | 3.0 | 17 |
| 25 | Landscape of Acquired Resistance to Osimertinib in <i>EGFR</i> -Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired <i>RET</i> Fusion. <i>Cancer Discovery</i> , 2018, 8, 1529-1539. | 9.4 | 342 |
| 26 | Widespread Chromosomal Losses and Mitochondrial DNA Alterations as Genetic Drivers in H ₄ arthle Cell Carcinoma. <i>Cancer Cell</i> , 2018, 34, 242-255.e5. | 16.8 | 185 |
| 27 | Outcomes of EGFR-mutant lung adenocarcinomas (AC) that transform to small cell lung cancer (SCLC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 8573-8573. | 1.6 | 1 |
| 28 | Clear Cell Change in Thyroid Carcinoma: A Clinicopathologic and Molecular Study with Identification of Variable Genetic Anomalies. <i>Thyroid</i> , 2017, 27, 819-824. | 4.5 | 21 |
| 29 | Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor. <i>Npj Precision Oncology</i> , 2017, 1, 5. | 5.4 | 49 |
| 30 | Primary Benign and Malignant Thyroid Neoplasms With Signet Ring Cells. <i>American Journal of Clinical Pathology</i> , 2017, 148, 251-258. | 0.7 | 16 |
| 31 | Invasive follicular variant of papillary thyroid cancer harboring the NRAS mutation Q61K and presenting with bone metastasisâ€”A case report. <i>International Journal of Surgery Case Reports</i> , 2017, 38, 180-184. | 0.6 | 3 |
| 32 | Clonal Evolution and the Role of Serial Liquid Biopsies in a Case of Small-Cell Lung Cancerâ€”Transformed <i>EGFR</i> Mutant Nonâ€”Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2017, 1, 1-7. | 3.0 | 8 |
| 33 | Tumor genomics and response to CDK 4/6 inhibitors for patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 1046-1046. | 1.6 | 4 |
| 34 | De novo ALK kinase domain mutations are uncommon in kinase inhibitor-na ⁺ ve ALK rearranged lung cancers. <i>Lung Cancer</i> , 2016, 99, 17-22. | 2.0 | 16 |
| 35 | Acquired Resistance to Crizotinib in NSCLC with MET [^] Exon 14 Skipping. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1242-1245. | 1.1 | 140 |
| 36 | Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in <i>ALK</i> -Rearranged Lung Cancer. <i>Cancer Discovery</i> , 2016, 6, 1118-1133. | 9.4 | 919 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 37 | Next-Generation Sequencing and Fluorescence in Situ Hybridization Have Comparable Performance Characteristics in the Analysis of Pancreaticobiliary Brushings for Malignancy. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 124-130. | 2.8 | 79 |
| 38 | Oncogenic PI3K mutations are as common as <i>AKT1</i> and <i>SMO</i> mutations in meningioma. <i>Neuro-Oncology</i> , 2016, 18, 649-655. | 1.2 | 221 |
| 39 | Impact of next-generation sequencing on the clinical diagnosis of pancreatic cysts. <i>Gastrointestinal Endoscopy</i> , 2016, 83, 140-148. | 1.0 | 119 |
| 40 | Heterogeneity Underlies the Emergence of <i>EGFR</i> T790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor. <i>Cancer Discovery</i> , 2015, 5, 713-722. | 9.4 | 429 |
| 41 | Identification of insertions in PTEN and TP53 in anaplastic thyroid carcinoma with angiogenic brain metastasis. <i>Endocrine-Related Cancer</i> , 2015, 22, L23-L28. | 3.1 | 5 |
| 42 | Detection of Dual IDH1 and IDH2 Mutations by Targeted Next-Generation Sequencing in Acute Myeloid Leukemia and Myelodysplastic Syndromes. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 661-668. | 2.8 | 31 |
| 43 | Metastasis-associated <i>MCL1</i> and <i>P16</i> copy number alterations dictate resistance to vemurafenib in a <i>BRAFV600E</i> patient-derived papillary thyroid carcinoma preclinical model. <i>Oncotarget</i> , 2015, 6, 42445-42467. | 1.8 | 40 |
| 44 | Targetable Signaling Pathway Mutations Are Associated with Malignant Phenotype in <i>IDH</i> -Mutant Gliomas. <i>Clinical Cancer Research</i> , 2014, 20, 2898-2909. | 7.0 | 146 |
| 45 | Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. <i>Nature Genetics</i> , 2014, 46, 161-165. | 21.4 | 408 |
| 46 | The Reprogramming of Tumor Stroma by HSF1 Is a Potent Enabler of Malignancy. <i>Cell</i> , 2014, 158, 564-578. | 28.9 | 298 |
| 47 | Targetable signaling pathway mutations and progression of <i>IDH</i> -mutant glioma. <i>Journal of Clinical Oncology</i> , 2014, 32, 2061-2061. | 1.6 | 0 |
| 48 | The feasibility to use minimal tumor samples for mutation analysis by multiplex PCR-based assay. <i>Journal of Clinical Oncology</i> , 2014, 32, e22060-e22060. | 1.6 | 0 |
| 49 | Multi-institutional multiplexed genetic analysis in lung adenocarcinoma (AC): The Lung Cancer Mutation Consortium (LCMC I) experience. <i>Journal of Clinical Oncology</i> , 2014, 32, 11030-11030. | 1.6 | 0 |
| 50 | Association of PIK3CA-activating mutations with more disseminated disease at presentation and earlier recurrence in glioblastoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 2029-2029. | 1.6 | 7 |
| 51 | The role of molecular profiling to differentiate multiple lung primary adenocarcinomas from intrapulmonary metastases from a lung primary. <i>Journal of Clinical Oncology</i> , 2013, 31, 7555-7555. | 1.6 | 0 |
| 52 | A retrospective analysis of the prevalence of <i>EGFR</i> or <i>KRAS</i> mutations in patients (pts) with crizotinib-naïve and crizotinib-resistant, ALK-positive non-small cell lung cancer (NSCLC). <i>Journal of Clinical Oncology</i> , 2013, 31, 8083-8083. | 1.6 | 1 |
| 53 | Impact of routine tumor genotyping on enrollment in targeted therapy trials for metastatic breast cancer (MBC): 4-year review. <i>Journal of Clinical Oncology</i> , 2013, 31, 533-533. | 1.6 | 0 |
| 54 | Impact of routine tumor genotyping on enrollment in targeted therapy trials for metastatic breast cancer (MBC): 4-year review. <i>Journal of Clinical Oncology</i> , 2013, 31, 145-145. | 1.6 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Activation of PI3K Signaling in Merkel Cell Carcinoma. <i>Clinical Cancer Research</i> , 2012, 18, 1227-1236. | 7.0 | 97 |
| 56 | Characteristics of NSCLCs harboring <i>NRAS</i> mutations.. <i>Journal of Clinical Oncology</i> , 2012, 30, 7532-7532. | 1.6 | 0 |
| 57 | Mutational Profiling of Multiple Myeloma Bone Marrow Aspirates As a Clinical Tool for Personalized Treatment of Myeloma. <i>Blood</i> , 2012, 120, 3990-3990. | 1.4 | 0 |
| 58 | Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. <i>EMBO Molecular Medicine</i> , 2010, 2, 146-158. | 6.9 | 370 |